RELATIVITY-047 Update: Novel Immunotherapy Duo Delays Disease Progression in Advanced Melanoma

Source: The ASCO Post, April 2022

A novel immunotherapeutic combination that targets PD-1 and the LAG-3 pathway significantly delayed disease progression as a first-line treatment of advanced or unresectable melanoma. Updated results of the global phase III RELATIVITY-047 trial validated the study’s initial findings and were presented in the ASCO Plenary Series, March 2022 session,1 by Georgina V. Long, MBBS, PhD, of the Melanoma Institute Australia, The University of Sydney, where she is Co-Medical Director and Chair of Melanoma Medical Oncology and Translational Research.

In the study, nivolumab and relatlimab were given as a fixed-dose combination to 714 previously untreated patients with advanced or metastatic melanoma. The initial results were recently published2 and summarized in the April 10 issue of The ASCO Post. Dr. Long reported the updated progression-free survival data and the first data on the secondary endpoints of overall survival and response rate.

READ THE ORIGINAL FULL ARTICLE